VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rVSV-EBOV
Vaccine Information
  • Vaccine Name: rVSV-EBOV
  • Target Pathogen: Ebola virus
  • Target Disease: Ebola hemorrhagic fever
  • Vaccine Ontology ID: VO_0004660
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Zaire ebolavirus (ZEBOV) (Falzarano et al., 2011).
    • Detailed Gene Information: Click Here.
  • GP from Cote d'Ivoire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Côte d’Ivoire ebolavirus (CIEBOV) (Falzarano et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein (Falzarano et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccination Protocol: Cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) (Falzarano et al., 2011).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The macaques were challenged with Bundibugyo ebolavirus (BEBOV)(Falzarano et al., 2011).
  • Efficacy: A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively) (Falzarano et al., 2011).
References
Falzarano et al., 2011: Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. The Journal of infectious diseases. 2011; 204 Suppl 3; S1082-1089. [PubMed: 21987745].